A topical combination ointment containing the antibiotic Mupirocin and the proteolytic enzyme Bromelain. Mupirocin is a unique antibiotic derived from Pseudomonas fluorescens, effective against Gram-positive bacteria, particularly Staphylococcus aureus and Streptococcus pyogenes. Bromelain, extracted from pineapple stems, acts as a debriding agent, breaking down necrotic tissue and fibrinous exudate, enhancing wound penetration of the antibiotic and promoting granulation. This combination is specifically formulated for infected wounds, burns, and ulcers where necrotic tissue impedes healing.
Adult: Apply a small amount (a ribbon of approx. 1-2 cm) to the affected area three times daily (TDS). Cover with a sterile gauze dressing if needed.
Note: 1. Clean and dry the affected area gently with saline or antiseptic. 2. Apply a thin layer of ointment using a sterile applicator or gloved hand. 3. Rub in gently until absorbed. 4. May be covered with a sterile non-occlusive dressing. 5. Wash hands before and after application. Do not use occlusive dressings unless advised by a physician.
Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl-tRNA synthetase. This prevents the incorporation of isoleucine into protein chains, leading to bacteriostatic effects at low concentrations and bactericidal effects at high concentrations. Bromelain exerts a selective chemical debridement action by hydrolyzing peptide bonds in denatured proteins, collagen, and fibrin present in necrotic tissue and exudates. It reduces inflammation, edema, and improves microcirculation, thereby facilitating the penetration of Mupirocin into the infected tissue.
Pregnancy: Category B (US FDA). No adequate and well-controlled studies in pregnant women. Use only if clearly needed and potential benefit justifies potential risk to the fetus. Topical application results in minimal systemic absorption.
Driving: No effect.
| Other Topical Products (e.g., corticosteroids, other antibiotics) | Potential for physical/chemical incompatibility. May alter absorption of either agent. | Moderate |
| Chloramphenicol (Topical) | Theoretical antagonism; avoid concurrent use. | Moderate |
| Anticoagulants (Warfarin, Acenocoumarol) - Systemic | Bromelain, if significantly absorbed, may have mild antiplatelet effects, potentially increasing bleeding risk. Monitor INR. | Low |
Same composition (Mupirocin (2% w/w) + Bromelain (5% w/w)), different brands: